% | $
Quotes you view appear here for quick access.

Pain Therapeutics Inc. Message Board

boorsrus 7 posts  |  Last Activity: May 20, 2016 8:28 PM Member since: Sep 20, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Chances of Remoxy approval.

    by svksudupa May 20, 2016 9:37 AM
    boorsrus boorsrus May 20, 2016 8:28 PM Flag

    An FDA mandated AdCom can oft times be be a propitious event. The outcome(s) of AdCom findings findings can serve as the predicates for other administrative actions.

    Specifically, one possible outcome could be a recommendation for Remoxy's approval AND Oxycontin's removal from the market (see the recent LATimes extensive investigative reporting regarding Purdue's "fraudulent" Oxycontin 12-hour release marketing claims).

    The pivotal issue here will be the demonstrable superiority of Remoxy as a "true" 12-hour release drug. Claims of "superior" abuse resistance qualities fall more into the realm of the subjective and are less likely to be decisive in any deliberations to recommend Oxycontins removal from the market.

    All of the above is perhaps wishful thinking, but stranger things have been known to happen in the past.

  • boorsrus by boorsrus May 13, 2016 5:41 PM Flag

    All facts and circumstances would seem to indicate that Remoxy (at long last!) will be approved. Moreover, Remoxy's market launch coincides with an avalanche of negative publicity (see LA Times investigative reporting) regarding Purdue's OxyContin and spurious (false) time release marketing claims. PTIE's Barbier has in the past implied that Remoxy's "true" 12-hour release mechanism (plus superior tamper/abuse resistance qualities) could knock OxyContin off the market. Maybe so...maybe not. My point is that DRRX's potential future royalty revenue stream could be significantly greater than that flowing from just another "me too" drug. This asset ,too, could be monetized (avoiding further dilution) for an amount that Remoxy's tortured path to market launch would never before have suggested possible.

  • Reply to


    by boorsrus May 3, 2016 4:59 PM
    boorsrus boorsrus May 4, 2016 10:00 AM Flag

    No doubt that DRRX has been to this point the proverbial "gang that can't shoot straight". However, do not discount the significance of insider buying. As regards Remoxy, it was returned by PFE to PTIE not because of doubts as to efficacy (and ultimate FDA approval) but because of an uneconomical royalty structure AND because Remoxy would have materially cannibalized sales of PFE's in-house abuse-deterrent ER drug candidate.

  • boorsrus by boorsrus May 3, 2016 4:59 PM Flag

    DRRX sells 13.8million shares at $1.25 ($17,250,000 gross proceeds) and the share price goes up BEFORE the offering is a fait accompli? Thus defying all logic?

    Not really. DRRX now has the cash (and the time) to fund and robustly execute what is hopefully the final Posimir Phase III AND to negotiate an optimal partnering agreement. (I do not believe a go-it-alone marketing strategy is or should be in the equation.) Adequate funds are now also at hand to fully fund on-going, early stage DUR-928 clinical trials.The financing transaction is also a bridge to the royalty revenue stream from Remoxy's approval and market launch in Q4 of this year. "Good" dilution is about as rare as a unicorn.

  • boorsrus by boorsrus Apr 12, 2016 6:16 PM Flag

    The FDA has accepted PTIE's Remoxy NDA resubmission. PDUFA date is September 25, 2016.

  • boorsrus by boorsrus Apr 11, 2016 3:25 PM Flag

    I think we all should take a deep breath and stop hyperventilating over the FDA's recent amicus curiae advisory to DRRX regarding Posismir. The outcome likely will be a more robust Phase III resubmission package, a greater probability of approval, more expansive labeling and enhanced third party partnering prospects. More time and money, yes...but, all facts and circumstances considered, not a bad prospective outcome.

  • Reply to

    Be Ready!

    by juliamarydd125140 Mar 22, 2016 10:24 AM
    boorsrus boorsrus Mar 22, 2016 5:14 PM Flag

    Wow! Yet another brilliant "Google it" post. Go Google yourself, Einstein.

2.32+0.02(+0.87%)May 27 4:00 PMEDT